Con Panousis

USPTO Granted Patents = 18 (Patent Applications = 12)

CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 11)

Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 66(Granted Patents)

Location History:

Bundoora, AU (2013 - 2022)
Melbourne, AU (2009 - 2023)
Parkville, AU (2015 - 2024)

Company Filing History:

Csl Behring Lengnau Ag

patents

4. 1 out of 4,177

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12071484 - Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein (2024-08-27),

2. 11840573 - CD131 binding proteins and uses thereof (2023-12-12),

3. 11505619 - Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease (2022-11-22),

4. 11466073 - Human serum albumin variants and uses thereof (2022-10-11),

5. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),

6. 11174321 - Method of treating atherosclerosis (2021-11-16),

7. 10808023 - Mutated von Willebrand factor (2020-10-20),

8. 10806774 - Mutated truncated von Willebrand Factor (2020-10-20),

9. 10513560 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2019-12-24),

10. 10047161 - Humanized anti-interleukin 3 receptor alpha chain antibodies (2018-08-14),

11. 9856326 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2018-01-02),

12. 9856325 - Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies (2018-01-02),

13. 9758585 - Compositions and methods for targeting type 1 interferon producing cells (2017-09-12),

14. 9617329 - Method of cloning nucleic acid (2017-04-11),

15. 9518127 - Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses (2016-12-13),

Title: The Innovative Contributions of Con Panousis in the Field of Biomedical Technology

Introduction

Con Panousis, a prolific inventor based in Bundoora, Australia, has made significant strides in the field of biomedical technology. With a remarkable portfolio of 17 patents, his groundbreaking work has revolutionized the healthcare industry and paved the way for novel treatment modalities.

Latest Patents

Panousis's latest patents showcase his ingenuity and dedication to advancing medical science. One of his notable inventions includes CD131 binding proteins and their uses, which have the potential to neutralize signaling by interleukin (IL) 3, IL-5, and granulocyte-macrophage colony stimulating factor (GM-CSF). Another groundbreaking patent involves the use of a FXIIa-inhibitor in the treatment of renal fibrosis and chronic kidney disease, demonstrating his commitment to addressing critical health challenges.

Career Highlights

Having worked with esteemed companies such as CSL Limited and CSL Behring GmbH, Panousis has honed his expertise and gained invaluable experience in the pharmaceutical and biotechnology sectors. His career highlights reflect a trajectory marked by innovation, vision, and a relentless pursuit of excellence.

Collaborations

Throughout his career, Panousis has collaborated with esteemed professionals in the field, including Andrew Donald Nash and Michael Wilson. These partnerships have led to fruitful exchanges of ideas, cutting-edge research initiatives, and the development of impactful solutions in healthcare.

Conclusion

In conclusion, Con Panousis stands as a trailblazer in the realm of biomedical technology, with a remarkable track record of inventions that have the potential to transform patient care and disease management. His drive for innovation, coupled with a passion for improving healthcare outcomes, solidifies his legacy as a pioneering inventor in the medical field.

This text is generated by artificial intelligence and may not be accurate.